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Abstract
Background: Oncocytes of the thyroid gland (Hu ¨rthle cells) are found in tumors and autoimmune diseases. They have a
unique appearance characterized by abundant granular eosinophilic cytoplasm and hyperchromatic nucleus. Their
pathogenesis has remained, thus far, unknown.
Methodology/Principal Findings: Using transgenic mice chronically expressing IFNc in thyroid gland, we showed changes
in the thyroid follicular epithelium reminiscent of the human oncocyte. Transcriptome analysis comparing transgenic to wild
type thyrocytes revealed increased levels of immunoproteasome subunits like LMP2 in transgenics, suggesting an important
role of the immunoproteasome in oncocyte pathogenesis. Pharmacologic blockade of the proteasome, in fact, ameliorated
the oncocytic phenotype. Genetic deletion of LMP2 subunit prevented the development of the oncocytic phenotype and
primary hypothyroidism. LMP2 was also found expressed in oncocytes from patients with Hashimoto thyroiditis and Hu ¨rthle
cell tumors.
Conclusions/Significance: In summary, we report that oncocytes are the result of an increased immunoproteasome
expression secondary to a chronic inflammatory milieu, and suggest LMP2 as a novel therapeutic target for the treatment of
oncocytic lesions and autoimmune hypothyroidism.
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Introduction
Oncocytes and lymphocytic infiltration are the pathologic
hallmarks of Hashimoto thyroiditis, one of the most prevalent
autoimmune diseases [1]. Thyroid oncocytes, also known as
Hu ¨rthle cells, Askanazy cells, or oxyphilic cells, derive from the
thyroid follicular cell and are characterized by an abundant,
eosinophilic and granular cytoplasm (the consequence of an
increased number of mitochondria) and a large, hyperchromatic
nucleus with prominent nucleoli [2,3]. Thyroid oncocytes are
found not only in Hashimoto thyroiditis but also in long-standing
Graves disease, multinodular goiter, benign thyroid neoplasms
(Hu ¨rthle cell adenoma and granular cell tumor), and malignant
thyroid neoplasms (Hu ¨rthle cell carcinoma, oncocytic variant of
papillary carcinoma, Warthin-like variant of papillary carcinoma,
and tall cell variant of papillary carcinoma) [4]. Oncocytes,
however, are not limited to the thyroid gland. They are also found
in other organs like kidneys and salivary glands.
The pathogenesis of oncocytes has remained overall unknown.
We have previously developed a mouse model of Hashimoto
thyroiditis based on the chronic production of interferon-gamma
(IFNc) by the thyroid follicular cell via transgenesis [5,6]. These
mice develop primary hypothyroidism as the direct consequence of
a chronic, cytokine-mediated, inhibition of thyroid function, a
phenotype that is present also in the absence of infiltrating
lymphocytes (obtained by crossing the transgenic mice to RAG
deficient mice) [5]. Interestingly, the thyrocytes of IFNc transgenic
mice assume a morphology resembling that of the human oncocyte.
This paper highlights the role of the immunoproteasome in the
pathogenesis of thyroid oncocytes and hypothyroidism. The
proteasome is a large barrel-shaped, proteolytic complex present
in the nucleus and cytoplasm of all cells to degrade proteins
marked with ubiquitin [7]. It is implicated in a number of
fundamental cellular activities such as the processing of antigens
presented by MHC class I molecules [8]. The constitutive
proteasome is made of a 20S catalytic core closed at both ends
by a 19S cap. The core is formed by four stacked rings, each made
of seven subunits: two alpha rings are on the sides and allow the
entrance of only denatured proteins; two beta rings are in the
center and perform the protease activity, reducing proteins to
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three beta subunits, b1, b2, and b5, which harbor postglutamyl
peptide hydrolytic-like, trypsin-like, and chymotrypsin-like activ-
ities, respectively. When the cell is stimulated by IFNc or other
inflammatory stimulants like tumor necrosis factor a, three
subunits in the beta rings and two in the cap are replaced by
new subunits called ib1 (or LMP2), ib2 (or LMP10), ib5 (or
LMP7), PA28a and PA28b, overall giving to the complex the
name of ‘‘immunoproteasome’’. The ib1 and ib2 subunits must be
assembled together, and similarly PA28a and PA28b, but
variations in immunoproteasome do exist. The genes coding for
LMP subunits are embedded within the class II region of the
MHC locus on chromosome 6, and are therefore in strong linkage
disequilibrium with the classical MHC class II molecules (DP, DR,
DQ) that have been associated with numerous autoimmune
diseases. In this paper we show that LMP2 is required for the
pathogenesis of thyroid oncocytes and hypothyroidism.
Results
Expression of IFNc in the Thyroid Transforms Normal
Thyrocytes into Oncocytes
The thyrocytes of thyr-IFNc transgenic mice crowded along a
scanty colloidal space (Figure 1A, middle panel), assuming a tall
and polygonal shape (Figure 1A, middle panel inset). Their
cytoplasm was granular and more eosinophilic than that of wild
type thyrocytes (Figure 1A, left panel), and the nucleus enlarged
with a prominent nucleolus, resembling the appearance of the
oncocytes (Hu ¨rthle cells) found in patients with Hashimoto
thyroiditis (Figure 1A, right panel). These cellular features were
confirmed by electron microscopy, which also revealed an
increased number and size of mitochondria in transgenic
thyrocytes (Figure 1B). Apoptosis of thyrocytes was not detected
by TUNEL in thyr-IFNc transgenic mice (Figure 1C).
Immunoproteasome Subunits Are Highly Expressed in
Oncocyte-Like IFNc Transgenic Thyrocytes
To characterize at the molecular level the pathologic changes
seen in thyr-IFNc transgenic thyrocytes, we used long serial
analysis of gene expression (Long SAGE) and compared gene
expression in transgenic and wild type isolated thyrocytes. A total
of 43,718 and 43,908 tags were collected from the transgenic and
wild type thyroid libraries, respectively. Major histocompatibility
complex (MHC) genes were the most highly expressed genes in
transgenic thyrocytes (rank 1, 5, 8 and 10 in Table S1 and 1, 2 and
3 in Table S2), whereas thyroglobulin dominated in wild type
controls (rank 1, 2, 6, 7, and 9 in Table S3 and 1, 2, 5 and 7 in
Table S4). Comparison of expression tags between thyr-IFNc
transgenic and wild type thyrocytes (Table 1) revealed that,
following the MHC genes, immunoproteasome subunits were
most abundantly expressed in transgenics. In particular, the beta
subunit type 8 (also known as LMP7) was increased 36 fold
(Table 1); then, the remaining four immunoproteasome subunits
were increased as follows: 14 fold for PA28b, 10 fold for beta
subunit type 9 (LMP2), 6 fold for PA28a, and 5 fold for beta
subunit type 10 (LMP10) (Figure 2A). The complete list of
expressed tags in the two thyroid libraries can be downloaded from
the GEO website (see Material and methods).
Long SAGE results were confirmed by reverse transcriptase
PCR and immunohistochemistry. The mRNA levels of all five
immunoproteasome subunits were significantly over-represented
in IFNc transgenic compared to wild type thyrocytes (Figure 2B).
Figure 1. Thyroid histopathology. (A) Thyroids from thyr-IFNc transgenic mice (middle panel) show a disrupted architecture, with scanty colloid
and thickened thyrocytes (inset), an appearance markedly different from that of wild type thyroids (left panel). Thyrocytes from thyr-IFNc transgenic
mice resemble human Hu ¨rthle cells, with eosinophilic and granular cytoplasm and hyperchromatic nucleus, mimicking the features of Hu ¨rthle cells
from a patient with Hashimoto thyroiditis (right panel). (B) By electron microscopy, thyr-IFNc transgenic thyrocytes appear taller (upper right panel)
than wild type thyrocytes (upper left panel), and contain more mitochondria (lower right panel, arrow) than wild type (lower left panel). (C) No
apoptosis was detected by TUNEL staining in thyr-IFNc transgenic thyrocytes.
doi:10.1371/journal.pone.0007857.g001
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PA28b were more abundant in IFNc transgenics than in controls
(Figure 2C). The increased expression of immunoproteasome
subunits was directly dependent upon IFNc signaling because it
disappeared when thyr-IFNc transgenic mice were crossed to mice
lacking Stat1 (Figure S1A) and could be reproduced in cultured
Fisher rat thyroid cells exposed to IFNc (Figure S1B). Based on
these findings we hypothesize that the oncocytic phenotype is a
consequence of increased immunoproteasome expression, second-
ary to chronic IFNc stimulation in our system.
Pharmacologic Inhibition of the Proteasome Ameliorates
the Oncocytic Phenotype
To assess pharmacologically whether proteasome inhibition
influenced the thyroid disease typical of thyr-IFNc transgenic mice,
we used MLN-273, a compound manufactured by Millennium
Pharmaceuticals, Inc. (Cambridge, MA) similar to Velcade, with a
inhibitory activity against purified proteasome of 0.2 nM [9]. Mice
(N=114:58 wild type and 56 transgenics) were first treated with
increasing doses of formulated MLN-273 (0, 0.1, 0.2, 0.3, 0.4, and
0.5 mg per Kg of mouse weight), following an administration cycle
of two injections per week for two weeks and one week of rest
(Figure 3A). Injections were begun during the first week of life
(typically on day 3), and ranged from a minimum of 4 to a
maximum of 24 (1 to 6 cycles). MLN-273 ameliorated the
oncocytic morphology in thyr-IFNc transgenic mice (Figure 3B,
open circles), starting at cumulative doses of 3.6 mg/Kg and
reaching a maximum at 6.0 mg/Kg (Figure 3B). An example of
improved morphology is shown in Figure 3C, which compares the
thyroid appearance of a mouse receiving 6 mg (closed arrow in
Figure 3B) to that of a mouse receiving 1.2 mg (open arrow in
Figure 3B). No effect on thyroid morphology was seen in wild type
mice receiving various doses of MLN-273 (Figure 3B, closed
circles), or the mannitol control (Figure 3B, open circles at 0 mg/
Kg). Serum T4 levels did not significantly improve upon MLN-
273 treatment (data not shown).
We repeated the experiment using a dose of 0.3 mg/Kg for 12
injections (cumulative dose of 3.6 mg/Kg) in 44 mice (28 wild type
and 16 transgenic). The oncocytic phenotype improved in thyr-
IFNc transgenic mice receiving MLN-273 compared to those
receiving mannitol (Figure 3D, p=0.022). The improvement was
also evident by an approximate 6-fold reduction in the weight of
thyroid-tracheal blocks (Figure 3E).
Genetic Deletion of LMP2, but Not LMP7, Corrects the
Oncocytic Phenotype
To assess genetically the effects of immunoproteasome block-
ade, we crossed thyr-IFNc transgenic mice to mice lacking either
LMP2 or LMP7. Thyr-IFNc transgenic - LMP2 knockout mice
showed a significantly improved thyroid morphology, with
minimal architectural disruption (Figure 4A left panel, and 4B),
and a limited number of oncocytes (Figure 4A middle panel, and
4C). Their thyrocytes resembled those of wild type littermates
(Figure 4A middle panel). The phenotype was intermediate in thyr-
IFNc transgenic mice having one copy of LMP2 (Figure 4A right
panel). The scattered mononuclear infiltration typical of thyr-IFNc
transgenic mice, instead, was not affected by the absence of LMP2,
and lymphocytes could still be seen in the thyroid interstitium of
Table 1. Comparison of gene expression by SAGE in thyrocytes isolated from thyr-IFNc transgenic (TG) or wild type (WT) mice
(shows the genes that displayed the highest TG over WT ratio).
Rank Gene Description Unigene ID Fold change (TG over WT)
1 H2-K1 MHC class I heavy chain precursor (H-2K(d)) Mm.16771 325
MHC class I (B7.2) cell surface antigen mRNA, 39 end Mm.380380
2 Ecotropic viral integration site 2a Mm.164948 182
Ia-associated invariant chain Mm.276499
SH2 domain containing 4A Mm.40974
3 Histocompatibility 2, Q region locus 8 (H2-Q8), mRNA Mm.296901 72
Transcribed locus Mm.34421
4 Connective tissue growth factor Mm.1810 51
5 Histocompatibility 2, class II antigen E beta (H2-Eb1) Mm.22564 38
C76746 Adult male epididymis cDNA, RIKEN full-length enriched library, clone:9230104M02 product Mm.358798
6 Proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7: LMP7) Mm.180191 36
7 Integral membrane protein 2B Mm.4266 32
8 Ribosomal protein L36 Mm.11376 21
Transcribed locus, strongly similar to NP_071949.1 ribosomal protein L36 [Rattus norvegicus] Mm.296314
Rpl36 Adult male heart cDNA, 60S RIBOSOMAL PROTEIN L36 homolog Mm.371604
Rpl36 Sulfatase modifying factor 1 (Sumf1) Mm.379094
9 Transcribed locus Mm.234875 20
RIKEN cDNA 0610037M15 gene Mm.221293
Histocompatibility 2, Q region locus 8 (H2-Q8) Mm.296901
Histocompatibility 2, Q region locus 1 Mm.327075
10 Hydroxysteroid (17-beta) dehydrogenase 4 Mm.277857 19
CD63 antigen Mm.371552
doi:10.1371/journal.pone.0007857.t001
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panel). Overall, these results suggest that LMP2 is directly involved
in the formation of oncocyte initiated by IFNc. During these
studies we also noted that thyroid follicular cells from mice lacking
only LMP2 were flatter than those observed in wild type controls
(Figure S2A), suggesting an effect of LMP2 on thyroid hormono-
genesis. In contrast to LMP2, lack of LMP7 did not improve the
disrupted thyroidal morphology or the oncocytic phenotype seen
in thyr-IFNc transgenic mice (Figure S2B).
Genetic Deletion of LMP2 Corrects the Hypothyroidism
and Growth Defect Induced by IFNc
We have previously reported that thyr-IFNc transgenic mice
develop primary hypothyroidism (low T4, high TSH, and low
iodine uptake) [5], goiter [6], and growth defect [6]. When crossed
to LMP2 deficient mice, the thyr-IFNc double mutant mice
corrected the hypothyroidism (Figure 4D, sixth group) and restored
a normal body weight in both males (Figure 4E left panel) and
females (Figure 4E right panel). These ameliorations were
intermediate in thyr-IFNc transgenics with a single copy of LMP2
(Figure 4A right panel, and 4B fifth group). The results indicate that
LMP2 is involved not only in oncocyte formation but also in the
development of hypothyroidism and growth defect initiated by
IFNc. LMP2 deficiency by itself had no influence on circulating T4
levels (Figure 4D, third group) or growth (Figure 4E, third group).
Thyroid accumulation of radioactive iodine in thyr-IFNc trans-
genics and thyr-IFNc transgenic-LMP2 knockout mice (Figure S3,
third and fourth group) was significantly lower than that of wild type
Figure 2. Thyroid expression of immunoproteasome subunits. (A) Immunoproteasome SAGE tag numbers, comparing thyr-IFNc transgenic
to wild type thyrocytes. (B) Immunoproteasome mRNA levels by semi-quantitative RT-PCR, comparing thyr-IFNc transgenic to wild type thyrocytes.
G3PDH is used as housekeeping control. (C) Immunoproteasome protein expression by immunohistochemistry: all subunits are increased in thyr-IFNc
transgenic thyroids when compared to wild type thyroids (inset).
doi:10.1371/journal.pone.0007857.g002
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second group) also had a significantly lower radioiodine accumula-
tion than wild type controls, in keeping with the flattened thyrocyte
morphology previously described (Figure S2A). LMP2 thus emerges
as an important regulator of thyroid structure and function, capable
of modulating iodine accumulation independently of IFNc.
LMP2 Is Expressed in Human Thyroid Oncocytes (Hu ¨rthle
Cells)
Given the key role of LMP2 in the induction of mouse
oncocytes, we assessed whether LMP2 was also expressed in
archival thyroid glands removed from patients with Hashimoto
thyroiditis, Graves disease, Hu ¨rthle cell adenoma, or Hu ¨rthle cell
carcinoma. LMP2 was expressed in all 19 Hashimoto thyroiditis
specimens (Table 2) with mention of Hu ¨rthle cells and in most of
those (5 of 6) where Hu ¨rthle cells were not mentioned by the
pathologist. LMP2 staining in Hashimoto thyroiditis was diffuse
throughout the section (Figure 5, left panel) and of strong intensity
(Figure 5, left panel inset), often useful to spot oncocytes in the
midst of the diffuse mononuclear cell infiltration typical of this
disease. LMP2 was also expressed in Hu ¨rthle cell adenomas
(Figure 5, middle panel) and carcinoma (Figure 5, right panel),
although levels varied greatly among patients and different areas of
Figure 3. Pharmacologic inhibition of proteasome using MLN-273. (A) Schedule of MLN-273 administration. (B) The oncocytic phenotype
typical of thyr-IFNc transgenic mice (open circles) improved upon MLN-273 administration in a dose-dependent fashion, beginning at cumulative doses
of3.6 mg/Kgofbodyweight.Nomorphologicalchangeswereobservedinthyr-IFNctransgenic treatedwithmannitolcontrol(opencircles,dose0),orin
wild type littermates (closed circles). (C) Thyroid morphology at 40X and 100X of a thyr-IFNc transgenic mouse treated with 4.8 mg/Kg MLN-273 (closed
arrow in Figure 2B), and another treated with 1.2 mg/Kg MLN-273. (D) Administration of 12 injections of 0.3 mg/Kg MLN-273 significantly improved the
oncocytic phenotype of thyr-IFNc transgenic mice. (E) The improvement was also evident macroscopically by a decrease in goiter size.
doi:10.1371/journal.pone.0007857.g003
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of LMP2 in Hashimoto thyroiditis, Hu ¨rthle cell adenoma, and
carcinoma (Figure S4B).
Overall the results suggest that oncocytes (Hu ¨rthle cells) arise in
response to a chronic inflammatory milieu within the thyroid
gland, forming a spectrum of morphological variants, with an
‘‘autoimmune Hu ¨rthle cell’’ at one end and a ‘‘neoplastic Hu ¨rthle
cell’’ at the other end of the spectrum.
Discussion
The study reports that LMP2, an immunoproteasome subunit,
is involved in the generation of oncocytes and hypothyroidism in a
mouse model of Hashimoto thyroiditis, and that is also expressed
in human oncocyte (Hu ¨rthle cell) lesions.
The role of LMP2 in the pathogenesis of autoimmune diseases
has been explored by a limited number of studies with conflicting
Figure 4. Genetic deletion of LMP2 ameliorates thyroid morphology and function. (A) Thyroid architecture of a thyr-IFNc transgenic-
LMP2 knockout mouse at 40X (left panel) and 160X magnification (middle panel). Thyroid architecture of a thyr-IFNc transgenic-heterozygous
mouse (right panel). (B) Disruption score of the thyroid gland architecture in the 6 genotypes. (C) Oncocytic score in the 6 genotypes. (D)
Serum total T4 levels in the 6 genotypes: lack of LMP2 ameliorates the hypothyroidism typical of thyr-IFNc transgenics. (E) Body weight of
male (left panel) and female (right panel) mice in the 6 genotypes: lack of LMP2 ameliorates growth retardation typical of thyr-IFNc transgenic
mice.
doi:10.1371/journal.pone.0007857.g004
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nity. For example, polymorphisms in the LMP2 have been
associated with autoimmune diseases like ankylosing spondylitis
[10], vitiligo [11], and psoriasis [12]. In addition, circulating levels
of LMP2 [13] and antibodies to LMP2 [14] are increased in
patients with connective tissues disorders like systemic lupus
erythematosus and Sjo ¨gren syndrome [15,16]. On the other hand,
one group has shown that the lack of splenic LMP2 is linked to
development of type 1 diabetes in the NOD mouse [17,18], a
report that has stimulated some controversy [19,20]. It is likely
that the tissue levels of LMP2 change throughout the course of the
autoimmune process in a tissue-specific manner. For example,
Vives-Pi and colleagues, studying eight patients with Graves
disease patients and four with type 1 diabetes, reported that
thyroid glands expressed high but variable levels of LMP2 and
LMP7, whereas pancreases had levels similar to those found in
healthy controls [21]. LMP2 increase did not always correspond to
a similar LMP7 increase, in keeping with the notion that these two
subunits are not always assembled together [22] in the
immunoproteasome, contrary to the pairing of LMP2 and
LMP10 [23]. Our finding that only the lack of LMP2, but not
LMP7, ameliorated diseases in thyr-IFNc transgenic mice supports
these observations.
In addition to demonstrating at the molecular and tissue levels
that LMP2 is a marker of oncocytes (Hu ¨rthle cells) in Hashimoto
thyroiditis, this study also reports that LMP2 is increased in
thyroid cancer. In patients with Hu ¨rthle cell adenomas or
carcinomas the expression of LMP2 was clear, although more
variable than that observed in Hashimoto thyroiditis. The
variability could be due to fine gradations in the oncocytic
phenotype: although oncocytes are defined by the combination of
morphological features, these features form a continuous spec-
trum, leading us to hypothesize that the oncocyte emerging in
Hashimoto thyroiditis (‘‘autoimmune Hu ¨rthle cell) might be
different from those found in cancer (‘‘neoplastic Hu ¨rthle cell’’).
This hypothesis remains to be tested. Further studies are also
needed to assess whether LMP2 levels correlate with clinical
outcomes in patients with Hu ¨rthle cell carcinoma.
LMP2 was used in this study as a therapeutic target to control
with MLN-273 the oncocytes present in transgenic mice over-
expressing IFNc in the thyroid gland. MLN-273 (PS-273) is an
emerging boronic acid proteasome inhibitor similar to Velcade
(bortezomib or PS-341) [24], a drug used in the treatment of
several cancers like multiple myeloma [25], and more recently
inflammatory [26] and autoimmune [27] diseases. MLN-273, like
Velcade, blocks the constitutive proteasome (b5 subunit) and the
immunoproteasome [28]. In vitro, MLN-273 effectively blocks the
development of Plasmodium parasites [29] and Mycobacterium
tuberculosis [30]. In vivo, MLN-273 halts the degradation of
dystrophin and dystrophin-associated proteins in a mouse model
of Duchenne muscular dystrophy [31]. It also improves the
glomerular filtration rate in a pig model of hypercholesterolemia
[32], although there is disagreement on whether targeting the
proteasome actually worsens atherosclerosis [33–35]. It remains to
be tested whether proteasome inhibition is effective in the
treatment of Hu ¨rthle cell carcinomas. As new inhibitors (like
IPSI-001) are being developed that preferentially target the
immunoproteasome rather than constitutive proteasome [28], it
is possible that this treatment modality will extend to a larger
number of autoimmune diseases. The treatment might be also
applicable to oncocytic lesions found in other organs, like kidneys,
salivary or adrenal glands.
Interestingly, the lack of LMP2 ameliorated the hypothyroidism
seen in thyr-IFNc transgenic mice, providing a novel explanation
for the pathogenesis of hypothyroidism typically found in patients
with autoimmune thyroiditis. Architectural disruption of the
thyroid gland by infiltrating lymphocytes and apoptosis of
thyrocytes have traditionally been considered the cause of
Table 2. Distribution and intensity of LMP2 expression by immunohistochemistry in Hu ¨rthle cells present in Hashimoto thyroiditis,
Hu ¨rthle cell adenoma, Hu ¨rthle cell carcinoma, and Graves disease.
strong LMP2 positive mild LMP2 positive no detectable LMP2 total
Hashimoto thyroiditis with mention of Hu ¨rthle cells 18 (95%) 1 0 19
Hashimoto thyroiditis without mention of Hu ¨rthle cells 3 (50%) 2 1* 6
Hu ¨rthle cell adenoma 5 (55%) 4 0 9
Hu ¨rthle cell carcinoma 3 (43%) 4 0 7
Graves disease 0 1 1 2
Autoimmune Hu ¨rthle cells strongly express LMP2.
*This thyroid pathological specimen contained only infiltrating lymphocytes and no thyroid cells.
doi:10.1371/journal.pone.0007857.t002
Figure 5. LMP2 expression in human thyroid. LMP2 expression marks Hu ¨rthle cells in patients with Hashimoto thyroiditis (left panel) Hu ¨rthle
cell adenoma (middle panel), or Hu ¨rthle cell carcinoma (right panel). The inset on the left panel shows that LMP2 is expressed specifically in Hu ¨rthle
cells (oncocytes) surrounded by the lymphocytic infiltration.
doi:10.1371/journal.pone.0007857.g005
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target of therapeutic interventions, which instead rely on the
administration of synthetic thyroxine. Although effective, this
symptomatic treatment is unsatisfactory in a discrete percentage of
hypothyroid patients, highlighting the need for new treatments
based on disease pathogenesis. Thyr-IFNc transgenic mice can,
therefore, provide a model to study chronic hypothyroidism, a
feature not found in most animal models of autoimmune
thyroiditis.
In summary, we report that thyroid oncocytes (Hu ¨rthle cells)
arise in the thyroid gland in response to a chronic inflammatory
milieu concomitant with LMP2 over expression, and suggest they
form a spectrum of morphological variants with an ‘‘autoimmune
Hu ¨rthle cell’’ at one end and a ‘‘neoplastic Hu ¨rthle cell’’ at the
other end of the spectrum. Considering increasing reports of the
association between Hashimoto thyroiditis and thyroid cancer
[36], we strongly propose that LMP2 might be a potential
therapeutic target for the protective treatment of oncocytic lesions
and hypothyroidism as well.
Materials and Methods
Mice
The study analyzed a total of 366 mice: 216 genetically
modified, and 150 C57BL/6 wild type littermate controls. The
genetically modified mice included the following genotypes, all on
the BL/6 background: thyr-IFNc transgenics (N=95) (a model
previously generated in our laboratory to express murine IFNc
specifically in thyroid follicular cells [5]), LMP2 knockout (N=29);
LMP2 heterozygous (N=19); LMP2 knockout/IFNc transgenic
(N=46); LMP2 heterozygous/IFNc transgenic (N=19); LMP7
knockout/IFNc transgenic (N=5); and STAT1 knockout/IFNc
transgenic (N=3). The thyr-IFNc transgenic mice were generated
as previously described. They express the murine IFNc gene under
control of the rat thyroglobulin promoter, to support transcription
specifically in thyroid follicular cells. LMP2 knockout mice and
LMP7 knockout mice (C57BL/6 background) were kindly gifted
from Dr. Whitton (The Scripps Research Institute, La Jolla, CA)
[37]. The following primers were used for genotyping for LMP2 or
LMP7 knockout mice, LMP2-2 primer: CCCGTGTCCC-
TCCGAGATAC and LMP2-4 primer: GGGATCCAGGAC-
CAGGAAAG to detect endogenous Psmb9 (LMP2) gene, LMP7A
primer: TCTATGGTGGCATCACTATGTT and LMP7B prim-
er: TGGTACACTGTGGGCGATTGAG to detect endogenous
Psmb8 (LMP7) gene, NEO A primer: CTTGGGTGGAGAGGC-
TATTC and NEO B primer: AGGTGAGATGACAGGAGATC
to detect mutant gene containing neo gene. STAT1 knockout mice,
also on the C57BL/6 background, were kindly donated by Dr.
David Levy (New York University Medical Center, New York,
NY) [38]. The following primers were used for genotyping for
LMP2 or LMP7 knockout mice, Stat P1 primer: GAGATAATT-
CACAAAATCAGAGAG and Stat P2 primer: CTGATCCAGG-
CAGGCGTTG to detect endogenous Stat1 gene, Stat P1 primer
and Stat P3 primer: TAATGTTTCATAGTTGGATATCAT to
detect mutant gene. All mice were bred in specific pathogen-free
facilities at Johns Hopkins University following protocols con-
formed to the JHU Animal Care and Use Committee guidelines.
For some experiments, mice were weighed at five-week old.
Human Thyroid Glands
Thyroid samples (N=43) for morphological and immunohisto-
chemical studies were obtained from the archival surgical
pathology specimens maintained in The Johns Hopkins Pathology
Department, using a protocol approved by the Institutional
Review Board. Samples included patients with Hashimoto
thyroiditis (N=25), Graves disease (N=2), Hu ¨rthle cell adenoma
(N=9), and Hu ¨rthle cell carcinoma (N=7).
Histopathology of Thyroid
After euthanasia, mouse tracheas with attached thyroids were
removed and fixed for 48 hours in the zinc-based Beckstead’s
solution or buffer-saturated formalin. The specimen was then
processed and embedded in paraffin. Six to 8 non sequential
sections (5 mm thick) were cut from the tissue block and stained
with hematoxylin and eosin (H&E). The same tissue block used for
H&E histopathology was used to cut sections for immunohisto-
chemistry.
TUNEL Staining to Detect Apoptosis in Mouse Thyroid
Glands
Formalin-fixed thyroid sections were deparaffinized in xylene,
rehydrated in decreasing concentrations of ethanol, and washed in
phosphatebuffersaline(PBS).Sectionswerethenincubatedatroom
temperature in proteinase K (20 mg/ml for 15 min), washed in
distilled water, and then incubated in hydrogen peroxide (0.3% for
10 min). TUNEL staining was performed using the ApopTag kit
(Chemicon, Temecula, CA). Sections were first equilibrated in the
kit buffer and then incubated for 1 hour at 37uC in a humidified
chamber with terminal deoxynucleotidyl transferase conjugated to
digoxigenin. Sections were then placed in a Coplin jar containing
working strength stop/wash buffer, agitated for 15 seconds, and
incubated for 10 min at RT. After washing in PBS, an anti-
digoxigenin antibody conjugated to peroxidase was applied for
30 min at RT. After washing, apoptosis-specific color was obtained
using diaminobenzidine, and overall morphology using Eosin Y
Alcoholic (Richard-Allan Scientific, Kalamazoo, MI).
Electron Microscopy of Mouse Thyroid Glands
Thyroid glands were fixed for 1 hour at room temperature in
0.1 M cacodylate buffer pH 7.2, supplemented with 3 mM CaCl2,
2% glutaraldehyde, and 4% paraformaldehyde. Glands were then
post-fixed for 1 hour at 4uC in cacodylate buffer supplemented
with 3 mM CaCl2 and 2% osmium tetroxide. Glands were then
washed for 30 min in 2% uranyl acetate, and dehydrated first with
increasing concentrations of ethanol (50%, 70%, 90% and 100%)
and then with propylene oxide. Glands were then infiltrated with a
propylene oxide-Epon mixture and embedded flat in Epon. Ultra-
thin sections were cut and analyzed for electron microscopy using
a Phillips CM12 (S)TEM microscope.
Long SAGE (Serial Analysis of Gene Expression) of CD45
Negative Mouse Thyrocytes
Thyroid lobes were collected from 3 thyr-IFNc transgenic female
mice, and 16 wild type female littermates. Lobes were incubated
immediately after dissection for 26 hours at 4uC in Eagle’s minimal
essential medium, supplemented with 1.2 U/mL dispase II (Roche
Applied Science, Indianapolis, IN) and 0.25 U/mL collagenase II
(Sigma, St. Louis, MO), to ensure a thorough diffusion of the
enzymes into the tissue. Lobes were then digested for 20 min at
37uC in a shaking water bath, and then briefly in cold PBS
containing 2 mM EDTA and 1% bovine serum albumin to stop the
digestion. After one wash, thyroid cells were first passed through
70 mMmeshfilter,toremovelarge tissue debris,andthenincubated
for 15 minutes at 4uC with anti-CD45 paramagnetic microbeads
(Miltenyi Biotech, Auburn, CA). After one wash, the mixture was
applied to a MS column (Miltenyi Biotech) in a magnetic separator:
the CD45 negative fraction (composed mainly of thyrocytes,
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phosphate-buffered saline, supplemented with 2 mM EDTA and
0.5%bovineserumalbumin.Themagneticseparationwasrepeated
once. CD45 negative thyroid cells were counted with trypan blue
and used to extract mRNA and perform Long SAGE as described
by Saha S et al. [39]. The SAGE sequencing data are available from
theGene Expression Omnibus repository ofthe National Centerfor
Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo),
using series record number GSE15114.
Expression of Immunoproteasome Subunit mRNA in
Mouse Thyroids by Semi-Quantitative Reverse
Transcriptase PCR
Thyroid lobes from 1-month-old thyr-IFNc transgenics (N=3)
and wild type littermates (N=3) were mechanically homogenized
to extract mRNA using oligo (dT)25 magnetic beads (Invitrogen,
Carlsbad, CA). Following DNase I (Invitrogen) treatment, mRNA
was reverse transcribed into cDNA using Superscript II RNase H
-
reverse transcriptase (Invitrogen). The five mouse immunoprotea-
some subunits using the following specific primers: PA28a forward
primer 59-CAAGCCAAGGTGGATGTGTTCC-39 and reverse
primer 59-GATCATTCCCTTGGTTTCTCCACG-39, PA28b
forward primer 59-GCAGGAGAAGGAAGTCCCTA-39 and
reverse primer 59-GATGGCTTTTCTTCACCCTTCGG-39,
LMP2 forward primer 59-ATGCTGCGGGCAGGAGCACC-
TACCG-39 and reverse primer 59-TCACTCATCGTAGAAT-
TTTGGCAGCT-39, LMP7 forward primer 59-ATGGCGT-
TACTGGATCTGTGCGGTGC-39 and reverse primer 59-TCA-
CAGAGCGGCCTCTCCGTACTTGT-39, LMP10 forward
primer 59-AGGAATGCGTCCTTGGAACACG-39 and reverse
primer 59-TCAATGCTCTCTGCAGCTTGGC-39. Mouse
G3PDH was amplified as quantitation control using forward
primer 59-GCATCTTGGGCTACACTGAG-39 and the reverse
primer 59-TCTCTTGCTCAGTGTCCTTG-39. The cDNA
from each proteasome sample was sequentially diluted and then
amplified for GAPDH. The dilutions that gave similar GAPDH
intensities were used for amplification of the proteasome subunits.
Expression of Immunoproteasome Subunit Proteins in
Mouse and Human Thyroids by Immunohistochemistry
Sections were deparaffinized with xylene, rehydrated with
decreasing concentrations of ethyl alcohol and finally PBS.
Formalin-fixed sections (human section) were, then, treated with
target retrieval solution (DAKO, Carpinteria, CA) for 10 min in
steamer; no target retrieval treatment for zinc-based Beckstead’s
solution-fixed mouse tissues. After cool down and washing with
PBS, endogenous peroxidase was blocked by treating the sections
with 3% H2O2 in PBS for 30 min at room temperature. After
blocking aspecific binding with 5% normal goat serum, sections
were incubated with the primary antibody; rabbit anti proteasome
subunit (LMP2, LMP7, LMP10, PA28a, and PA28b; Biomol
International, L.P., Plymouth Meeting, PA), in PBS supplemented
with 1% bovine serum albumin, and incubated overnight at 4uCi n
a humid chamber. Primary antibody was diluted for human thyroid
sections as following; LMP2 (1:200), LMP7 (1:2,000), LMP10
(1:1,000), PA28a (1:4,000), PA28b (1:20,000). Primary antibody
was diluted for mouse sections as following; LMP2 (1:400), LMP7
(1:10,000), LMP10 (1:4,000), PA28a (1:12,000), PA28b (1:40,000).
After washing, the biotin-conjugated secondary antibody (affinity
purified goat anti-rabbit IgG, from DAKO, diluted 1:1000 in PBS-
1%BSA) was incubated for 1 hr at room temperature. After rinsing,
peroxidase-conjugated streptavidin (DAKO) was diluted 1:500 in
PBS and incubated for 30 min at RT. Finally, sections were
incubated for 5 min with NovaRED substrate or DAB substrate
(both from Vector Laboratories, Burlingame, CA) for color
development and then rinsed in distilled water. Sections were
counter-stained with hematoxylin (Vector Laboratories).
Proteasome Inhibitor Administration
To block pharmacologically the function of the proteasome,
thyr-IFNc transgenic mice and wild type littermates were injected
i.p with MLN-273. This compound, a gift from Millennium
Pharmaceutical Inc. (Cambridge, MA), blocks like Velcade
(Bortezomib) the constitutive proteasome (b5 subunit) and the
immunoproteasome [28]. MLN-273 was formulated as 1 part
(8.3%) active compound and 11 parts (91.7%) mannitol vehicle.
Mice received MLN-273 or mannitol control twice a week for 2
weeks, then rested for a week, and then were injected again until
reaching cumulative formulated doses of 1.2, 2.0, 2.5, 3.6, 4.8, and
6.0 mg/Kg (Figure 3A).
Assessment of Thyroid Function by Serum Total T4 Levels
Serum total thyroxine (T4) was determined by a competitive
RIA (Diasorin, Stillwater, MN), according to the manufacturer’s
instructions. Briefly, ten ml of serum were added to plastic tubes
coated with a monoclonal antibody directed against T4. Then,
1 ml of tracer buffer containing
125I-T4 was added to the tubes
and the solution incubated at room temperature for 45 min.
Tubes were then decanted and counted for 1 min in a gamma
counter (Isodata-520, from Titertek, Huntsville, AL). Total T4
concentrations were extrapolated from a standard curve generated
using six T4 standards ranging from 0 to 20 mg/dL.
Radioactive Iodine Uptake (RAIU)
Iodine uptake was determined using radioactive iodine. Mice
were fed with iodine-deficient diet (TD95007 from HARLAN
TEKLAD, Indianapolis, IN) for 3 weeks. Mice were injected with
10 mCi of
125I (carrier-free, Amersham) intraperitoneally. Mice
were sacrificed 4 hours after injection of radioactive iodine, and
thyroid lobes and muscle (negative control) were excised, weighed
and counted using a gamma counter. Iodine uptake was
normalized dividing the count by the weight of each tissue.
Detection of Thyroidal Gene Expression by Northern
Hybridization
After thyroid lobes were excised and homogenated in TRIZOL
(Invitrogen, Carlsbad, CA), total RNA was extracted following
manufacture protocol. 10 mg of total RNA was separated by 1%
agarose gel electrophoresis and analyzed by Northern blot for the
expression of LMP2. The signal from G3PDH was also obtained
to adjust for the amount of RNA loaded in each lane; G3PDH
probe was synthesized using pTRI-GAPDH-Mouse (Ambion,
Austin, TX). Probe signals were quantified using the BAS-1500
Bioimaging Analyzer (Fuji Photo Film Co., Japan).
Statistical Analysis
Differences among the six genotypes were assessed using the
non-parametric Kruskal-Wallis test, followed by Wilcoxon sing-
rank test for the pairwise comparisons. All analyses were
performed using Stata statistical software, release 10 (from Stata
Corp., College Station, TX).
Supporting Information
Figure S1 (A) LMP2 and LMP10 protein expression by
immunohistochemistry in thyr-IFNc transgenic-STAT1 knockout
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proteasome subunits, as compared to that found in thyr-IFNc
transgenic-STAT1 wild type controls (insets). (B) LMP2 RNA
expression by Northern blotting in Fisher rat thyroid follicular cells
(FRTL-5 line) stimulated with IFNc. Total RNA was extracted
from FRTL-5 cells after 0, 3, 12, 24, 48 or 72 hours of IFNc
stimulation, and hybridized with a rat LMP2 cDNA probe by
mRNA expression was assessed by Northern hybridization. IFNc
strongly induced LMP2 expression, beginning at 12 hours post-
stimulation and plateauing at 48 hours. No oncocytic changes
were seen morphologically in the thyroid cells during these culture
time points.
Found at: doi:10.1371/journal.pone.0007857.s001 (1.75 MB TIF)
Figure S2 (A) Thyroidal morphology of mice lacking just LMP2:
the thyroid architecture is preserved (left panel), but thyrocytes are
flatter (right panel) than wild type thyrocytes (right panel, inset). (B)
Thyroid morphology of thyr-IFNc transgenic mice lacking LMP7:
the absence of LMP7 has no effect on the oncocytic phenotype
induced by IFNc.
Found at: doi:10.1371/journal.pone.0007857.s002 (9.59 MB TIF)
Figure S3 Radioactive iodine accumulation in thyroid. The
radioactive iodine accumulation is decreased in mice lacking
LMP2, in thyr-IFNc transgenic mice, and in thyr-IFNc transgenic
mice lacking LMP2. No significant difference was observed among
LMP2 knockout, thyr-IFNc transgenics, and thyr-IFNc transgenic/
LMP2 knockout mice.
Found at: doi:10.1371/journal.pone.0007857.s003 (0.27 MB TIF)
Figure S4 Histological analysis of human Hu ¨rthle cells. (A)
LMP2 expression varies in different areas of Hu ¨rthle cell
adenomas: expression is lower (left panel, inset) in areas with
more complex histopathology (left panel) than in areas with a more
uniform appearance (right panel). (B) LMP7 expression in
Hashimoto thyroiditis (left panel), Hu ¨rthle cell adenoma (middle
panel), and Hu ¨rthle cell carcinoma (right panel).
Found at: doi:10.1371/journal.pone.0007857.s004 (3.13 MB TIF)
Table S1 Top 10 genes expressed in thyr-IFNc transgenic mouse
thyrocytes (total tag # is 43,718).
Found at: doi:10.1371/journal.pone.0007857.s005 (0.06 MB
DOC)
Table S2 Top 10 genes expressed only in thyr-IFNc transgenic
mouse thyrocytes.
Found at: doi:10.1371/journal.pone.0007857.s006 (0.04 MB
DOC)
Table S3 Top 10 genes expressed in wild-type mouse thyrocytes
(total tag # is 43,908).
Found at: doi:10.1371/journal.pone.0007857.s007 (0.05 MB
DOC)
Table S4 Top 10 genes expressed only in wild-type mouse
thyrocytes.
Found at: doi:10.1371/journal.pone.0007857.s008 (0.03 MB
DOC)
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